Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
https://www.zacks.com/stock/news/2262623/bristol-myers-bmy-q1-loss-narrower-than-expected-sales-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-2262623
Apr 25, 2024 - Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance. However, Opdivo sales disappoint.
0
Pfizer (PFE) Rises Higher Than Market: Key Facts
https://www.zacks.com/stock/news/2259603/pfizer-pfe-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2259603
Apr 22, 2024 - Pfizer (PFE) reachead $26.26 at the closing of the latest trading day, reflecting a +1% change compared to its last close.
0
Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
https://www.zacks.com/stock/news/2254409/pharma-stock-roundup-jnj-to-buy-shockwave-medical-other-pipeline-regulatory-news?cid=CS-ZC-FT-analyst_blog|stock_roundup-2254409
Apr 12, 2024 - J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.
0
Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?
https://www.zacks.com/stock/news/2253861/will-novavax-s-nvax-strategic-reshaping-curb-cash-burn?cid=CS-ZC-FT-analyst_blog|zer_report_update-2253861
Apr 11, 2024 - To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.
0
Will Pfizer's (PFE) New Drugs Provide a Boost to 2024 Sales?
https://www.zacks.com/stock/news/2253860/will-pfizer-s-pfe-new-drugs-provide-a-boost-to-2024-sales?cid=CS-ZC-FT-analyst_blog|zer_report_update-2253860
Apr 11, 2024 - Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
0
Top Analyst Reports for UnitedHealth, Pfizer & BlackRock
https://www.zacks.com/commentary/2253408/top-analyst-reports-for-unitedhealth-pfizer-blackrock?cid=CS-ZC-FT-research_daily-2253408
Apr 10, 2024 - Today's Research Daily features new research reports on 12 major stocks, including UnitedHealth Group Incorporated (UNH), Pfizer Inc. (PFE) and BlackRock, Inc. (BLK).
0
Pfizer (PFE) Declines More Than Market: Some Information for Investors
https://www.zacks.com/stock/news/2252211/pfizer-pfe-declines-more-than-market-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2252211
Apr 08, 2024 - In the latest trading session, Pfizer (PFE) closed at $26.58, marking a -0.3% move from the previous day.
0
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
https://www.zacks.com/stock/news/2248948/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2248948
Apr 02, 2024 - Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
0
Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study
https://www.zacks.com/stock/news/2246921/moderna-mrna-posts-upbeat-data-from-next-gen-covid-jab-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2246921
Mar 27, 2024 - Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.
0
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
https://www.zacks.com/stock/news/2245553/bayer-bayry-banks-on-pipeline-progress-amid-challenges?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245553
Mar 25, 2024 - Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.
0
Page 1>